Cutaneous Lymphoma

Phase I Clinical Trial Of Adeno Interferon-(gamma) Product Initiated

Published in Gene Therapy Weekly, January 31st, 2002

Transgene announced the initiation of a Phase I clinical trial of its Adeno Interferon (gamma) (Ad-IFN(gamma)) immunotherapeutic product candidate for the treatment of cutaneous lymphoma.

The trial will be conducted in Zurich and will include at least nine patients with either advanced cutaneous T cell lymphoma (CTCL) or multilesional B cell lymphoma. CTCL is a non-Hodgkin lymphoma that affects the T cells of the immune system. It is a chronic, highly symptomatic, debilitating malignancy that infiltrates the skin. Tumor stage CTCL is generally considered to be incurable.

The Phase I clinical trial will evaluate the safety, the immune effects and...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Gene Therapy Weekly

Source: Gene Therapy Weekly (2002-01-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry